JAK2/STAT3 signaling pathway

Overview

The JAK2/STAT3 signaling pathway is an intracellular signal transduction cascade that relays cytokine and growth factor signals from the cell surface to the nucleus, coupling receptor engagement directly to changes in gene transcription. Janus kinase 2 (JAK2) is a non-receptor tyrosine kinase constitutively associated with the cytoplasmic tails of cytokine receptors; ligand binding — most prominently by interleukin-6 (IL-6), but also by growth factors, leptin, and interferons — brings receptor-bound JAK2 molecules into proximity, where they activate one another by transphosphorylation and then phosphorylate signal transducer and activator of transcription 3 (STAT3) on its conserved tyrosine residue, Tyr705. Phosphorylated STAT3 (pSTAT3) dimerizes, translocates to the nucleus, and drives transcription of target genes governing proliferation, survival, angiogenesis, and inflammation, including antiapoptotic effectors such as B-cell lymphoma 2 (Bcl-2). Under normal physiology the cascade is transient and self-limiting, restrained by negative feedback from suppressor of cytokine signaling (SOCS) proteins; loss of that restraint yields the sustained, constitutive STAT3 activation characteristic of disease. Closely related receptor–kinase couplings, such as TYK2-JAK1, transduce overlapping cytokine inputs through the same STAT family.

The pathway's breadth of downstream output places it at the intersection of oncology, immunology, and metabolic disease. In tumors it integrates signals from the microenvironment — inflammatory cytokines including IL-6 and interleukin-1β, chemokines, and stromal mediators — and cooperates with hypoxia-inducible factor 1-alpha (HIF-1α), Akt/protein kinase B, mitogen-activated protein kinase 1 (MAPK1), and nuclear β-catenin to sustain glycolytic metabolic reprogramming, epithelial-mesenchymal transition, and immune evasion via checkpoint ligands of the PD-1/PD-L1 axis. Beyond cancer, JAK2/STAT3 activity contributes to renal tubulointerstitial fibrosis and ferroptosis in diabetic kidney disease, to microglia-driven neuroinflammation and pyroptosis after cerebral ischemia-reperfusion injury, and to inflammatory liver injury. Its therapeutic tractability is well established: ATP-competitive JAK inhibitors including ruxolitinib and momelotinib are used clinically in myelofibrosis, JAK2 serves as a benchmark target in structure-based drug design campaigns, and a large body of natural product pharmacology — spanning compounds such as bufalin, bruceine D, and rosmarinic acid — pursues STAT3 suppression as a mechanism of action.

Recent Publications Summary

Recent publications have continued to position JAK2/STAT3 signaling as a central node in cancer, inflammatory disease, and metabolic pathology. In lung squamous cell carcinoma, CXCL2 was linked to the IL-6/JAK2/STAT3 axis and the immune microenvironment through integrated multi-omics analyses, functional assays, pathway enrichment, and protein-level validation 42151497May. In hepatocellular carcinoma, CD276 was shown to bind pSTAT3 after tyrosine kinase inhibitor treatment, translocate to the nucleus, and cooperate with pSTAT3 to drive CD36 transcription, fatty acid uptake, lipid accumulation, and resistance to TKIs 41956200Apr. A separate HCC study identified endotrophin-CD44 signaling as a pro-tumorigenic loop in which CD44 activation of STAT3 promoted epithelial-mesenchymal transition, proliferation, sorafenib resistance, and a STAT3-dependent feedback circuit sustaining endotrophin production 41671381Feb. In prostate cancer, novel napabucasins bearing sulfonylpiperazine scaffolds were developed as direct STAT3 inhibitors, with the lead compound YN11 binding the STAT3 SH2 domain, suppressing STAT3 phosphorylation, and inhibiting tumor growth in vivo 41849947Mar.

Several studies examined natural products and traditional formulations that modulate JAK2/STAT3 signaling in renal, pulmonary, and neurologic disease models. Bufalin was reported to alleviate diabetic kidney disease by post-transcriptionally suppressing STAT3, reducing ferroptosis, and mitigating tubulointerstitial fibrosis in db/db mice and high-glucose-treated renal tubular epithelial cells 42186424May. Shenxiao decoction was described as improving podocyte injury in diabetic nephropathy through upregulation of RUNX3 and inhibition of the JAK2/STAT3 pathway 41621765Feb. In non-small-cell lung cancer, bruceine D was reported to suppress progression by inhibiting STAT3-mediated glycolysis 42100892May. In allergic airway inflammation, xanthatin was described as directly targeting STAT3 to inhibit TSLP release and NK2 cell polarization 41621761Feb. In cerebral ischemia-reperfusion injury, hyperbaric oxygen preconditioning was reported to disrupt the LRG1-HIF-1α-IL-6-STAT3 amplification loop and attenuate pyroptosis 42053428Apr. Codonopsis pilosula polysaccharides were also shown to regulate the JAK2-STAT3 pathway to inhibit microglial activation in an anti-aging model 41895995Mar.

Other studies highlighted JAK2/STAT3 signaling in immune regulation, fibrosis, and metabolic reprogramming. Fasudil was reported to exert anti-inflammatory and antinociceptive effects in a fibromyalgia model by suppressing ObRb-linked JAK2/STAT3 hyperactivation downstream of leptin signaling 41942028Apr. In hepatocellular carcinoma, the CD276-pSTAT3-CD36 axis was linked to lipid metabolic rewiring and resistance to tyrosine kinase inhibitors, while metformin was shown to suppress PD-L1 expression through SLC5A11-dependent activation of AMPK and downstream JAK2-STAT1-IRF1 downregulation, illustrating related but distinct cytokine-signaling crosstalk in tumor immunity 41956200Apr41690450Feb. In acute liver injury, STAT3 emerged as one of the hub genes identified by network pharmacology and transcriptomic analysis alongside JUN, ESR1, and CTNNB1 42007886Apr. In thoracic aortic dissection, Xuefu Zhuyu decoction was reported to attenuate disease by regulating vascular smooth muscle cell phenotypic switching and oxidative stress via the JAK2/STAT3/HIF-1α pathway 41679360Feb. In type 2 diabetes, Xiehuang San was described as targeting CLCF1-STAT3 to restore insulin signaling 41628867Feb.

The pathway also appeared in studies of hematologic disease and therapeutic development. In primary immune thrombocytopenia, CDK8/CDK19 inhibition promoted regulatory T-cell conversion by augmenting STAT5 phosphorylation while suppressing STAT3 phosphorylation under IL-6-driven conditions 41770851Mar. In AGS-related interferonopathies, JAK1/2 inhibitors improved immunological and dermatological symptoms, although neurological benefit was limited and the authors noted that disease complexity extends beyond the JAK-STAT pathway 41871482Mar. In acute myeloid leukemia treated with venetoclax and hypomethylating agents, JAK2 mutation was among the genetic lesions associated with inferior overall survival 41671569Feb. Finally, structure-based and AI-assisted discovery efforts continued to focus on JAK2 as a drug target, including a geometry-aware de novo design framework that generated JAK2-binding scaffolds with favorable predicted ligand efficiency and an AI-experimental pipeline that identified multiple JAK2 inhibitors with sub-10 μM IC50 values 42118199May41593209Jan.

What Changes, What Holds

1. The pathway is now implicated in additional tumor-intrinsic resistance and metabolic rewiring loops
NEW DIRECTION CXCL2, CD276, and endotrophin/CD44 extend the pathway’s cancer role beyond the Overview’s general account of proliferation, survival, angiogenesis, and immune evasion by tying JAK2/STAT3 to lipid uptake, epithelial-mesenchymal transition, and tyrosine kinase inhibitor resistance in specific tumors 42151497May41956200Apr. The direct STAT3 inhibitor work also reinforces druggability, but the main update is that STAT3 can sit inside feedback circuits that sustain therapy resistance rather than merely downstream of inflammatory input 41671381Feb41849947Mar.

2. Natural products and physical or herbal interventions continue to validate JAK2/STAT3 as a disease-modifying node across nonmalignant models
REINFORCES These studies mostly sharpen the baseline rather than change it: they keep placing JAK2/STAT3 at the center of diabetic kidney injury, airway inflammation, ischemic brain injury, and microglial activation, consistent with the Overview’s fibrosis, neuroinflammation, and inflammatory injury framing 42186424May41621765Feb. The added value is mechanistic specificity, including post-transcriptional STAT3 suppression, but the class of claim remains the same—pathway inhibition tracks with reduced pathology, not a new biological role.

3. The pathway is increasingly tied to metabolic control and vascular remodeling, but the established signaling logic still holds
REINFORCES Fasudil’s effect downstream of leptin, the HCC CD276-pSTAT3-CD36 axis, and the vascular smooth muscle/HIF-1α findings all fit the Overview’s description of JAK2/STAT3 as a hub for metabolic reprogramming, inflammatory crosstalk, and fibrosis-related remodeling 41942028Apr41956200Apr41679360Feb. The metformin report and the acute liver injury network analysis add related signaling context, yet they do not displace the baseline mechanism; they mainly broaden the list of tissues and upstream cues in which it operates 41690450Feb42007886Apr.

4. Therapeutic targeting of JAK2/STAT3 remains a live drug-development strategy, with no reversal of the baseline account
REINFORCES The hematologic and discovery studies continue to support JAK2 as a tractable target and STAT3 as a relevant downstream effector, while also showing that pathway suppression can be incomplete or context-dependent in complex immune disease 41770851Mar41871482Mar. The AML association with inferior survival is consistent with the pathway’s disease relevance, and the AI/structure-based inhibitor work strengthens the translational case rather than changing what the pathway is understood to do 41671569Feb42118199May.

Overview update candidates: CD276-pSTAT3-CD36-driven lipid uptake and TKI resistance in HCC; endotrophin/CD44-STAT3 feedback sustaining EMT and sorafenib resistance; STAT3 as a direct drug target in prostate cancer; bufalin-linked post-transcriptional STAT3 suppression in diabetic kidney disease; hyperbaric oxygen disruption of the LRG1-HIF-1α-IL-6-STAT3 loop; JAK2 as a continuing drug-design target.